Posted by Michael Wonder on 29 Mar 2023
Takeda receives approval to manufacture and market Entyvio subcutaneous injection in Japan for the maintenance treatment of moderate to severe ulcerative colitis
27 March 2023 - Subcutaneous administration provides a new treatment option for patients with ulcerative colitis who have had an inadequate response to existing therapies.
Osaka, Japan, March 27 – Takeda today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of Entyvio syringes and pens for subcutaneous injection as maintenance therapy for moderate to severe ulcerative colitis.
